Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study

doi:10.3748/wjg.15.5946

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 47

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2491)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

291

HTML

1853

Figures (1-4)

180

Tables (1-5)

167

Sum=2491

Dec 21, 2009 (publication date) through Jul 4, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Dec 21, 2009; 15(47): 5946-5952
Published online Dec 21, 2009. doi: 10.3748/wjg.15.5946

Full Size Figure Download Figure

Figure 1 Mean hepatitis C virus (HCV)-RNA levels during the first 24 wk of treatment in patients with HCV genotype 1 infection receiving PEG-IFNα2a plus ribavirin (PR) or PEG-IFNα2a plus ketoprofen (PK) or PEG-IFNα2a plus ribavirin and ketoprofen (PRK).

Citation: Gramenzi A, Cursaro C, Margotti M, Balsano C, Spaziani A, Anticoli S, Loggi E, Salerno M, Galli S, Furlini G, Bernardi M, Andreone P. Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: A phase II study. World J Gastroenterol 2009; 15(47): 5946-5952
URL: https://www.wjgnet.com/1007-9327/full/v15/i47/5946.htm
DOI: https://dx.doi.org/10.3748/wjg.15.5946